About mepolizum ab
Interleukin-5 monoclonal antibody
Used for
- Add-on treatment for severe eosinophilic asthma in children aged 6–11 years.
- Treatment of chronic rhinosinusitis with nasal polyps in adults.
- Treatment of eosinophilic granulomatosis with polyangiitis in adults.
- Treatment of hypereosinophilic syndrome in eligible patients.
Usual adult dose
Usually 100 mg injected under the skin every 4 weeks for asthma, nasal polyps, or eosinophilic granulomatosis with polyangiitis; hypereosinophilic syndrome usually requires 300 mg every 4 weeks.
Usual dose in children
For asthma, ages 6–11 years: 40 mg injected under the skin every 4 weeks. Not established for other listed uses in children.
Common side effects
- Headache
- Injection-site reactions
- Back pain
- Fatigue
Important warnings
- Not for sudden asthma attacks or acute breathing problems.
- Serious allergic reactions can occur, including delayed reactions.
- Treat existing parasitic worm infections before starting; monitor for new infections.
- Do not stop inhaled or oral corticosteroids suddenly.
Pregnancy
Human pregnancy information is limited; use only when the potential benefit justifies potential risk.
Breastfeeding
It is unknown whether mepolizumab passes into human milk; weigh breastfeeding benefits against treatment needs.
Interactions
- No established major drug interactions; formal interaction studies are limited.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.